TABLE 1.
Activity of SQ641 in 1.75% TPGS solution and in Micelles in a C57BL/6 mouse model of TBa
| Treatment group | Formulation | Route (frequency) of drug administration | Log no. of CFU/lung (mean ± SD) |
P for statistical differenceb from:
|
||
|---|---|---|---|---|---|---|
| EC | LC | INH | ||||
| Untreated | ||||||
| Early control | NO | 7.46 ± 0.21 | ||||
| Late control | NO | 8.09 ± 0.18 | ||||
| Treated with INH | ||||||
| 25 mg/kg | Solution | Gavage (5/wk) | 5.10 ± 0.59 | |||
| Treated with SQ641 | ||||||
| 50 mg/kg | Solution | i.p. (5/wk) | 6.70 ± 0.20 | 0.03 | <0.0015 | |
| 25 mg/kg | Solution | i.v. (2/wk) | 6.10 ± 0.34 | <0.0015 | 0.075 | |
| 100 mg/kg | Micelles | i.p. (5/wk) | 6.15 ± 0.35 | <0.0015 | ||
| 50 mg/kg | Micelles | i.v. (2/wk) | 6.01 ± 0.21 | <0.0015 | 0.015 | |
a
Therapy with drugs was initiated 3 weeks after M. tuberculosis H37Rv infection. Mice were treated with drugs for 4 weeks. NO, no treatment; EC, early control; LC, late control.
b
Statistical significance was calculated by ANOVA and Student's t test; for multiple comparisons, Bonferroni correction was used. Differences were considered significant if P was <0.05.